Vaccines Access
ACIP Recommendation by Product and Age
Routine versus risk-based versus shared clinical decision. Coverage design is the demand switch. 2026 childhood-schedule edits are stayed.
Influenza (seasonal)
- Population:
- Everyone 6 months+
- ACIP posture:
- Routine annual
- Why it matters:
- Coverage benchmark. 2025-26 adult uptake 46.5% (NIS-FRVM).
COVID (seasonal)
- Population:
- Adults; narrower than pandemic
- ACIP posture:
- Seasonal; age and risk rules have tightened
- Why it matters:
- Coverage 17.5% of adults 18+ in 2025-26. Recommendation design is the demand switch.
RSV vaccines (Arexvy, Abrysvo, mRESVIA)
- Population:
- 75+; 50-74 at increased risk
- ACIP posture:
- Single dose, not annual. No product preference.
- Why it matters:
- Arexvy sales were £1,238m in 2023, £590m in 2024 and £593m in 2025. GSK cites a more limited ACIP recommendation for ages 60 to 74 and channel inventory consumption.
Beyfortus (nirsevimab)
- Population:
- Infants entering first RSV season
- ACIP posture:
- Routine infant prevention
- Why it matters:
- Competes with maternal Abrysvo. Sanofi said Beyfortus was not hit by the 2026 childhood-schedule edit.
Enflonsia (clesrovimab)
- Population:
- Infants entering first RSV season
- ACIP posture:
- FDA approved Jun 2025; ACIP vote is in the stayed set
- Why it matters:
- CRS notes the June 2025 infant-RSV vote may not currently sit on the CDC schedule. Coverage is unsettled.
Abrysvo (maternal)
- Population:
- Pregnancy, 32-36 weeks
- ACIP posture:
- Maternal indication
- Why it matters:
- Only RSV vaccine with a pregnancy label. Not split out in Pfizer's product table.
Shingrix
- Population:
- Adults 50+
- ACIP posture:
- Routine
- Why it matters:
- IRA $0 Part D copay. US immunization 44%; ex-US is now 66% of GSK sales.
Prevnar family / Capvaxive / Vaxneuvance
- Population:
- Pediatric routine; adult pneumococcal by age and risk
- ACIP posture:
- Routine pediatric; adult share fight
- Why it matters:
- VFC catalog is the public-sector price. Adult is pharmacy and Part D.
Gardasil 9
- Population:
- 9-26 routine; 27-45 shared clinical decision
- ACIP posture:
- Routine through 26
- Why it matters:
- Shared decision-making is a coverage binary. China destock is a tender risk, not an ACIP risk.
CDC Posted Immunization Schedule, July 2025
The child and adult tables CDC currently labels as live under the 16 Mar 2026 stay. Not uptake. Not a stayed ACIP vote. Enflonsia's June 2025 vote is omitted on purpose.
Hepatitis B
- CDC posted posture:
- Routine childhood series. Adult table: 2, 3, or 4 doses depending on vaccine
- Ages on the posted tables:
- Birth dose, then 1 to 2 months and 6 to 18 months on the child table
- Roster P&L:
- HEPLISAV-B is the 2-dose adult product in the Sanofi-Dynavax deal. Pediatric HepB sits in combination books.
Rotavirus
- CDC posted posture:
- Routine infant
- Ages on the posted tables:
- 2 and 4 months (RV1) or 2, 4, and 6 months (RV5)
- Roster P&L:
- Merck RotaTeq $673M in 2025. GSK Rotarix is inside established and Gavi volume.
DTaP / Tdap
- CDC posted posture:
- Routine childhood plus adolescent booster
- Ages on the posted tables:
- DTaP on the infant table (2, 4, 6, 15 months). Tdap: 1 dose at 11 to 12 years (CDC child notes)
- Roster P&L:
- Sanofi PPH and GSK established. Not a single SKU P&L.
Hib
- CDC posted posture:
- Routine infant
- Ages on the posted tables:
- 2, 4, then 12 to 15 months (third or fourth dose per notes)
- Roster P&L:
- Inside Sanofi PPH.
Pneumococcal conjugate
- CDC posted posture:
- Routine pediatric. Adult 50+ if never received a PCV (MMWR 2025 adult schedule)
- Ages on the posted tables:
- Infant 2, 4, 6, and 12 to 15 months (PCV15 or PCV20) on the child table. Adult table: see notes; MMWR 2025: universal at 50+ if no prior PCV15/20/21
- Roster P&L:
- Pfizer Prevnar family $6.494B. Merck Vaxneuvance and Capvaxive.
IPV
- CDC posted posture:
- Routine childhood
- Ages on the posted tables:
- 2, 4, 6 to 18 months, and 4 to 6 years
- Roster P&L:
- Inside Sanofi PPH.
Influenza
- CDC posted posture:
- Routine annual from 6 months
- Ages on the posted tables:
- 1 or 2 doses annually by age and prior doses. Adult 65+ prefers HD, recombinant, or adjuvanted
- Roster P&L:
- Sanofi flu/COVID bundle (unsplit). CSL Seqirus. GSK influenza £303M.
COVID-19
- CDC posted posture:
- Seasonal; see notes
- Ages on the posted tables:
- Posted child and adult tables point to notes, not a fixed annual age band
- Roster P&L:
- Pfizer Comirnaty and Moderna Spikevax. Recommendation design is the demand switch. This row is the posted schedule, not uptake.
MMR and varicella
- CDC posted posture:
- Routine two-dose
- Ages on the posted tables:
- First dose 12 to 15 months. Second dose 4 to 6 years
- Roster P&L:
- Merck ProQuad / M-M-R II / Varivax $2.451B.
Hepatitis A
- CDC posted posture:
- Routine childhood two-dose
- Ages on the posted tables:
- 12 to 23 months
- Roster P&L:
- Tender and travel adjacency. Not a named 2025 franchise line here.
HPV
- CDC posted posture:
- Routine adolescent; adult catch-up through 26; 27 to 45 shared clinical decision
- Ages on the posted tables:
- CDC child notes: routinely recommended at 11 to 12 years (can start at 9); catch-up through 18. Adult table: 19 to 26 (2 or 3 doses); 27 to 45 shared clinical decision
- Roster P&L:
- Merck Gardasil. Shared decision-making is a coverage binary.
MenACWY
- CDC posted posture:
- Routine adolescent two-dose
- Ages on the posted tables:
- CDC child notes: 2-dose series at 11 to 12 years and 16 years
- Roster P&L:
- GSK Menveo / Penmenvy. Sanofi MenQuadfi sits inside the unsplit meningitis/travel/endemic bundle.
MenB
- CDC posted posture:
- Shared clinical decision at 16 to 23, not a routine series
- Ages on the posted tables:
- CDC child notes: healthy adolescents 16 to 23 (preferred 16 to 18), 2 doses 6 months apart based on shared clinical decision-making. Increased-risk: 3-dose series
- Roster P&L:
- GSK Bexsero. Shared decision is the demand switch, not a second COVID.
RSV infant (nirsevimab)
- CDC posted posture:
- Routine infant prevention on the child table
- Ages on the posted tables:
- 1 dose depending on maternal RSV vaccination status, with 8 to 19 months notes
- Roster P&L:
- Sanofi/AZ Beyfortus. Merck Enflonsia is FDA-approved; its June 2025 ACIP vote, which the CDC Director adopted (Merck 10-K, 24 Feb 2026), is in the set stayed on 16 Mar 2026 and is not treated as coverage here.
RSV vaccine (Abrysvo, adults)
- CDC posted posture:
- Maternal seasonal; adult 75+ and 50 to 74 at increased risk
- Ages on the posted tables:
- Child table: seasonal in pregnancy. Adult table: 75+ and 50 to 74 (see notes). Single dose, not annual
- Roster P&L:
- Pfizer Abrysvo. GSK Arexvy and Moderna mRESVIA share the adult row. The 27 Apr 2026 adult-page amendment added the April 2025 RSV language as adopted by HHS.
Shingles (RZV)
- CDC posted posture:
- Routine adult 50+
- Ages on the posted tables:
- 2 doses at 50 to 64 and 65+
- Roster P&L:
- GSK Shingrix. No 2026 US commercial competitor.
CDC VFC Catalog Prices, April 2026
What the US public sector pays versus private list. Gardasil $275, Prevnar 20 $200, Beyfortus $444 at CDC cost.
WHO 2024 Dose Volume vs Value
7.2 billion doses and $66 billion of value. DCVMN and SII win volume. IFPMA wins the P&L. UNICEF and self-procuring MICs buy most doses.
BARDA and SNS: Freeze-Dried Jynneos
Option exercises, not pharmacy demand. $156.8M bulk in 2024 through $97M remaining freeze-dried doses for 2027.
BARDA awards Bavarian Nordic a ten-year contract for freeze-dried smallpox vaccine, potential value above $539M
Initial award of $100M for bulk manufacturing and storage; initial options include $299M for filling and freeze-drying. The vaccine was then named IMVAMUNE. Contract HHSO100201700019C.
BARDA orders 5.5M liquid-frozen Jynneos doses for the mpox outbreak: 500,000 on 10 Jun, 2.5M on 1 Jul and 2.5M on 15 Jul 2022
Filled from bulk already made under earlier BARDA contracts, most of which was to be converted into about 13 million freeze-dried doses. Bavarian Nordic said in Aug 2023 that replenishing the bulk was necessary to deliver the freeze-dried version.
BARDA orders $156.8M of Jynneos bulk
$139.7M of bulk, manufactured and invoiced in 2024, partly replenishes inventory used in the 2022 mpox response. About $17M covers services in 2025-2027, including storage of vaccine doses in the US.
Additional BARDA order of $63M for bulk and freeze-dried doses
Bulk, planned for 2025, further replenishes the 2022 mpox inventory. The order also supports manufacturing of 1 million freeze-dried doses, delivered in 2026.
FDA approves a freeze-dried, two-vial presentation of Jynneos
Supplement to the Jynneos BLA, for adults 18 and older. Bavarian Nordic cites advantages in transportation, storage conditions and shelf life for long-term stockpiling.
BARDA exercises $143.6M of options for 2026 delivery
Covers converting bulk into freeze-dried doses, plus supplemental payments for all doses under the freeze-dried contract, triggered by the demonstration of an extended shelf-life. Deliveries planned for 2026.
BARDA exercises $97M more of options, securing the remaining doses of the original 11.5M-dose freeze-dried order
Mostly bulk, to replace bulk consumed for liquid-frozen doses in the 2022-23 outbreak, invoiced in 2026. Freeze-dried doses are manufactured and delivered in 2027. The company raised 2026 Public Preparedness revenue guidance to DKK 2.3B-2.5B.
US Vaccine Policy Timeline, 2025 to 2026
ACIP reconstitution, the 17-to-11 childhood-schedule rewrite, lower US vaccine sales in Q1 2026, and the March 2026 stay. Live litigation.
HHS Secretary terminates all 17 ACIP members; new members are appointed on 11 Jun 2025
Further members were appointed on 11 Sep 2025 and 13 Jan 2026. The 16 Mar 2026 court order below stayed the appointments of 13 of them and all votes taken by that ACIP.
HHS memo revises the childhood immunization schedule: routine recommendations fall from 17 to 11
ACIP was not involved in the change. Some recommendations were limited to high-risk groups and others moved to shared clinical decision-making.
Sanofi, Pfizer and Merck report lower US sales for several vaccines in Q1 2026
Sanofi: US meningitis, travel and endemic vaccines down 17.5%. Pfizer: US Comirnaty down 43% and US Prevnar family down 10%, with lower Comirnaty utilization attributed primarily to a narrower recommendation. Merck: lower US Gardasil sales, primarily from unfavorable public-sector purchasing patterns.
Massachusetts district court stays the January 2026 childhood-schedule memo, 13 ACIP appointments and the votes taken by that ACIP
Preliminary relief under 5 U.S.C. 705, not a final judgment. The government filed a notice of appeal on 29 Apr 2026.
Senate confirms Erica Schwartz as CDC director, 51 to 44
Roll call vote EX. 220. Cloture on the nomination was agreed 51 to 43 (EX. 219) the same day.
HHS names Karim Mikhail CBER director and Michael Davis CDER director
FDA lists Mikhail as CBER director, Davis as CDER director and Kyle Diamantas as Acting Commissioner. Not confirmed in a primary source as of 2026-11-01: the 8 Sep 2026 announcement date and that both had been serving as acting directors.
Senate HELP Committee holds confirmation hearing on Heidi Overton for FDA commissioner
A hearing, not a confirmation vote. The nominee was introduced by Senator Hagerty. FDA lists Kyle Diamantas as Acting Commissioner.
China Gardasil Destock
International sales fell from $6.158B to $2.592B. WHO: China was half of 2024 HPV financial value, all private sector.